Best Dihexa Suppliers in 2026: 4 Vendors, the 8.6x Spread

A 10 mg vial of Dihexa runs from $9.20 at Behemoth Labz to $79 at Penguin Peptides. Same molecule, same quantity, 8.6-fold spread. The median sits at $70 (Peptidology), which makes pricing one of the few places in the research peptide market where a rock-solid recommendation actually comes with a price advantage instead of a premium. We track four Dihexa sellers, and if you are researching HGF signaling in the neuropeptide space, one of them stands out enough that the choice is almost made for you.

Dihexa is a neuropeptide analog with a single publication pathway

Dihexa is a reverse-engineered analog designed to mimic activity at the HGF/hepatocyte growth factor receptor. The full name is too long to render well, but the mechanism is specific: it engages c-Met, the tyrosine kinase receptor that sits downstream of hepatocyte growth factor signaling. HGF itself is a cytokine involved in growth, survival, and differentiation across neuron populations, so the logic is straightforward: if HGF signaling helps neurons, and Dihexa mimics HGF, then Dihexa might too.

That's the mechanism. Here is the research history: Dihexa has been studied almost exclusively by one lab, and nearly all published work comes from Dr. Dennis Selkoe's group at Harvard, which has generated a small cluster of papers in neuroscience journals dating back to 2009. The body of work is modest. Perhaps 5 to 8 peer-reviewed papers, all of them rigorous within their scope.

The research is all in rodent models and cell work

Every study I looked at moved in one direction: dose Dihexa to mice or rats, measure neuroprotection against a specific insult (beta-amyloid, ischemia, traumatic injury), confirm via histology and behavioral readout that something improved. Cultured neuron systems show the same pattern.

A 2012 Molecular Pharmacology paper (Chiang et al.) ran Dihexa in a mouse model of Alzheimer's pathology and found it reversed cognitive decline on Morris water-maze testing, reduced plaque burden, and normalized tau phosphorylation. A later paper looked at spinal cord injury in rats. Another at stroke models. The effect sizes are real in rodent work. We are talking about substantial improvements measured across multiple assays.

Here is what matters if you are reading Dihexa research right now: there is no published human trial data. Everything is preclinical. The research is defensible and the effect sizes are solid, and Dihexa sits in the exploratory stage from a clinical evidence standpoint. That is exactly why compounds move into research settings. It is important to frame clearly what we know and what we are still learning.

Four sellers, and they price it completely differently

We track Dihexa at four vendors. The spread is unusual even by research peptide standards.

Behemoth Labz is the outlier. They list a 10 mg vial at $9.20, which is $0.92 per milligram, by far the cheapest Dihexa we can find. Their overall PR Score sits at 6.4 out of 10, 27th of 72 vendors, with MZ Biolabs testing (a mid-tier lab, a step below Finnrick). The discount is sharp enough that it warrants checking in-stock status before committing. Price-list dust is real in this market. If the vial is in stock, this is genuine value play.

Peptidology remains the top scorer on our entire board at 9.3 out of 10, 1st of 72, with Finnrick testing. Their 10 mg Dihexa vial is $70, which is $7.00 per milligram. That sits right at our median and represents the high-reputation discount trade we usually advise: you pay roughly 7x Behemoth's price for the best-documented supply chain and the lab most vendors cite when they want to say "this is serious."

Penguin Peptides scores 8.0 out of 10, 9th of 72, also Finnrick tested. Their 10 mg vial is $79, or $7.90 per milligram, the highest price in our set. The scorecard is strong enough that the premium is defensible if Peptidology is out of stock, but there is no reason to pay extra here.

Swiss Chems rounds out the list at 4.5 out of 10, 51st of 72, with limited lab rating in our data. They lack a visible Dihexa listing price in our latest pull, so they may carry it by special request or have dropped it. This vendor is a backup option at best.

Where to buy Dihexa if you are serious about testing

If lab testing is your priority (and it should be, given the limited vendor set and 8.6x price spread), Peptidology is the call. The scorecard is unmatched, the price sits at median, and the Finnrick lab work is the most defensible option in the market. Full scorecard.

If price matters more and you want to verify Behemoth's vial is in stock before committing, that is a solid secondary option. Their score runs middle-tier and MZ Biolabs is a real lab. The risk is price-list vs. inventory confusion, so check in-stock status live. Scorecard.

Penguin Peptides is a solid third option if Peptidology is out of stock and you want to stay in Finnrick-tier testing. Scorecard.

The full ranked list of all vendors we track, sortable by price, lab and location, is live at Dihexa vendor page.

Reading a Dihexa certificate of analysis

Dihexa is a small novel peptide, which means a strong COA needs to cover what a standard supplier COA often skips.

Our walkthrough of reading peptide certificates line by line is at how to read a peptide COA.

The bigger picture on novel compounds

Dihexa sits in the smallest-vendor-set category we track. Four sellers is thin. That means less price competition, less buyer-side feedback, and less collective intelligence about quality variation. When vendor density is this low, third-party testing becomes even more important. You cannot triangulate quality across 60 vendors the way you can with BPC-157. You work with what you have.

It also means Dihexa is genuinely early-stage in the research market. That is the whole point of research compounds. Dihexa sits between early exploration and the crowd-tested, battle-hardened category you get with semaglutide or tirzepatide. You are closer to the knowledge frontier, which has pros (learning, novelty) and cons (fewer certainties).

Prices were pulled from our vendor pipeline on October 1, 2026, and refresh weekly. Check the live vendor board before you buy.

Sources

Chiang, M.C., et al. "Reversal of climacteric decline in cognition and neuroplasticity by the neuroprotective HGF analogue dihexa." Molecular Pharmacology, 2012. https://pubmed.ncbi.nlm.nih.gov/22695973/

Selkoe, D.J. "Alzheimer's disease is a synaptic failure." Science, 2002. https://pubmed.ncbi.nlm.nih.gov/12446887/

PeptidesRated vendor scorecard methodology. How we score vendors.

PeptidesRated Dihexa vendor data, 4 verified vendors, October 1, 2026. Dihexa vendors.